Pharmavax

Pharmavax AS is a Norwegian biotechnology company specializing in the development of optimized pharmaceutical formulations for pain management and oncology. The company's primary focus is on creating superior combinations of local anesthetics, such as lidocaine and prilocaine, to enhance pain relief during medical and dental procedures. Pharmavax is currently advancing its lead candidate, PVX 2024-01, through Phase 2 clinical trials, with a specific emphasis on patient populations with genetic mutations that affect anesthetic efficacy. Based in Ski, Norway, the company leverages its proprietary intellectual property to address significant unmet needs in the global anesthesia and analgesia markets.